Charissa Psion Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-06-2024
- Paid Up Capital ₹ 0.50 M
as on 20-06-2024
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2.80 M
as on 20-06-2024
- Satisfied Charges ₹ 3.00 M
as on 20-06-2024
- Revenue 34.25%
(FY 2017)
- Profit -12.92%
(FY 2017)
- Ebitda -42.58%
(FY 2017)
- Net Worth 4.20%
(FY 2017)
- Total Assets 6.31%
(FY 2017)
About Charissa Psion Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.80 M. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Premakumar Sankaran and Rekha Pramakumar serve as directors at the Company.
- CIN/LLPIN
U02423TN2006PTC061437
- Company No.
061437
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2006
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Charissa Psion Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Premakumar Sankaran  | Director | 06-Nov-2006 | Current |
| Rekha Pramakumar | Director | 23-Mar-2010 | Current |
Financial Performance of Charissa Psion Pharmaceuticals.
Charissa Psion Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 34.25% increase. The company also saw a substantial fall in profitability, with a 12.92% decrease in profit. The company's net worth moved up by a moderate rise of 4.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Charissa Psion Pharmaceuticals?
In 2017, Charissa Psion Pharmaceuticals had a promoter holding of 78.00% and a public holding of 22.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Lakshmi Vilas Bank Limited Creation Date: 14 Sep 2015 | ₹2.80 M | Open |
Dhanlaxmi Bank Limited Creation Date: 18 Mar 2015 | ₹0.50 M | Satisfied |
Dhanlaxmi Bank Limited Creation Date: 05 Jun 2010 | ₹2.50 M | Satisfied |
How Many Employees Work at Charissa Psion Pharmaceuticals?
Unlock and access historical data on people associated with Charissa Psion Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Charissa Psion Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Charissa Psion Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
